Physician profile
Eileen Quillin
NPI 1124587928
$2,503.95
in general payments reported to CMS, 2019-2025
19 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 88% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $172 · 2023: $50.68 · 2024: $799 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.23 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $565.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $520.82 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $296.11 | 2021-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $268.64 | 2022-2025 | Livdelzi |
| Lilly USA, LLC | $132.23 | 2024-2025 | Omvoh |
| Genzyme Corporation | $129.31 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $109.47 | 2024-2025 | Dupixent |
| Pfizer INC. | $77.18 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $59.60 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $59.25 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $50.86 | 2024-2025 | Voquezna |
| Organon LLC | $48.84 | 2024-2025 | Nexplanon, Renflexis, Hadlima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.65 | 2022-2023 | Xifaxan |
| Aimmune Therapeutics, INC. | $32.83 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $31.39 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $22.73 | 2024 | Ibsrela |
| Novo Nordisk INC | $20.81 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $17.18 | 2025 | Rezdiffra |
| Endogastric Solutions, INC | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Quillin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.